pharmaceutical industry news
May 08, 2018
Atara Biotherapeutics hires; Minor effects of multiple genes determine migraine risk; Celgene set to refile ozanimod
Atara Biotherapeutics hires ex-Genentech SVP to lead its global R&D program Atara Biotherapeutics recently hired Dietmar Berger, M.D., Ph.D., as its R&D global head. During the time in Genentech, Berger was involved in the approval of several drugs including the PD-L1 checkpoint inhibitor Tecentriq. Berger w...
Read More...
May 03, 2018
Horizon Discovery declines Abcam’s USD 367 million takeover bid
Horizon Discovery declines Abcam’s USD 367 million takeover bid Horizon Discovery has recently rejected a buyout bid worth USD 367 million from Abcam. Horizon Discovery is an expert in gene editing technique and has issued a strong rejection to the offer of Abcam. Horizon’s board believes that the bid unde...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
